Cargando…

Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study

Background: Epilepsy is a common symptom of brain tumors and is often pharmacoresistent. Among new antiseizure medications (ASMs) Brivaracetam (BRV) has been approved as adjunctive treatment for focal seizures and it was tested in non-oncological patient populations. This is the first study that ret...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maschio, Marta, Maialetti, Andrea, Mocellini, Cristina, Domina, Elisabetta, Pauletto, Giada, Costa, Cinzia, Mascia, Addolorata, Romoli, Michele, Giannarelli, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466736/ https://www.ncbi.nlm.nih.gov/pubmed/32973649 http://dx.doi.org/10.3389/fneur.2020.00813

Ejemplares similares

Impact of epilepsy and its treatment on brain metastasis from solid tumors: A retrospective study
por: Maschio, Marta, et al.
Publicado: (2022)

Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study)
por: Coppola, Antonietta, et al.
Publicado: (2020)

Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany
por: Willems, Laurent M., et al.
Publicado: (2018)

Safety and efficacy of brivaracetam in children epilepsy: a systematic review and meta-analysis
por: Song, Ting, et al.
Publicado: (2023)

Perampanel in brain tumor‐related epilepsy: Observational pilot study
por: Maschio, Marta, et al.
Publicado: (2020)

First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study
por: Menzler, Katja, et al.
Publicado: (2019)

Α Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice
por: Stefanatou, Maria, et al.
Publicado: (2021)

Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2022)

Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015)

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open‐label trial
por: Farkas, Mark Kristof, et al.
Publicado: (2022)

Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
por: Zahnert, Felix, et al.
Publicado: (2018)

In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells
por: Rizzo, Ambra, et al.
Publicado: (2017)

Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases
por: Costa, Cinzia, et al.
Publicado: (2022)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design
por: Bast, Thomas, et al.
Publicado: (2022)

Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals
por: Beaty, Silky, et al.
Publicado: (2021)

The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy
por: Perversi, Fabio, et al.
Publicado: (2023)

Emerging drugs for partial-onset epilepsy: a review of brivaracetam
por: Gao, Lan, et al.
Publicado: (2016)

New developments in the management of partial-onset epilepsy: role of brivaracetam
por: Coppola, Giangennaro, et al.
Publicado: (2017)

Brivaracetam in the treatment of epilepsy: a review of clinical trial data
por: Feyissa, Anteneh M
Publicado: (2019)

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Overnight switch from levetiracetam to brivaracetam. Safety and tolerability
por: Abraira, L., et al.
Publicado: (2021)

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics
por: Nardi Cesarini, Elena, et al.
Publicado: (2020)

Risk Assessment by Pre-surgical Tractography in Left Hemisphere Low-Grade Gliomas
por: Ius, Tamara, et al.
Publicado: (2021)

Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years
por: Schoemaker, Rik, et al.
Publicado: (2017)

Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy
por: Savastano, Ersilia, et al.
Publicado: (2021)

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
por: Maschio, Marta, et al.
Publicado: (2018)

The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma
por: Maschio, Marta, et al.
Publicado: (2019)

Lacosamide on background eeg activity in brain tumor‐related epilepsy patients: A case series study
por: Maschio, Marta, et al.
Publicado: (2018)

Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
por: Niquet, Jerome, et al.
Publicado: (2017)

Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center
por: Maschio, Marta, et al.
Publicado: (2017)

Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study
por: Maschio, Marta, et al.
Publicado: (2022)

Perceptions of Modulatory Factors in Migraine and Epilepsy: A Multicenter Study
por: Ur Özçelik, Emel, et al.
Publicado: (2021)

Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers
por: Lerche, Holger, et al.
Publicado: (2020)

Brivaracetam in treating epileptic encephalopathy and refractory focal epilepsies in patients under 14 years of age
por: RUSSO, Angelo, et al.
Publicado: (2021)

Editorial: Epilepsy in older adults: From physiopathology to improvements in diagnosis and management
por: Romigi, Andrea, et al.
Publicado: (2022)

Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
por: Klotz, Kerstin A., et al.
Publicado: (2019)

Epilepsy and Alzheimer’s Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies
por: Leo, Antonio, et al.
Publicado: (2022)

Effectiveness and tolerability of perampanel monotherapy in children with newly diagnosed focal epilepsy
por: Zhao, Fen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i72hlh4bi6m3c8l5su655bvke2